Emerging roles for pharmacists in clinical implementation of pharmacogenomics

Pharmacotherapy

Volumn 34, Issue 10, 2014, Pages 1102-1112

  Owusu Obeng, Aniwaa ^a,b   Weitzel, Kristin W ^c,d   Hatton, Randy C ^e   Staley, Benjamin J ^e   Ashton, Jennifer ^e   Cooper Dehoff, Rhonda M ^c,f   Johnson, Julie A ^c,d,f  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b MOUNT SINAI HOSPITAL   (United States)

^c UNIVERSITY OF FLORIDA HEALTH   (United States)

^d UNIVERSITY OF FLORIDA   (United States)

^e UNIVERSITY OF FLORIDA   (United States)

^f UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

clinical implementation; pharmacist roles; pharmacogenetics; pharmacogenomics

Indexed keywords

CLOPIDOGREL; CYTOCHROME P450 2C19; CYTOCHROME P450 2D6; THIOPURINE METHYLTRANSFERASE;

ARTICLE; CLINICAL DECISION MAKING; CLINICAL EDUCATION; CORONARY STENTING; CYP2C19 GENE; CYP2D6 GENE; DRUG SAFETY; EDUCATION PROGRAM; EVIDENCE BASED MEDICINE; GENOTYPE; HEALTH PROGRAM; HUMAN; MEDICAL ETHICS; MEDICAL INFORMATICS; PATIENT CARE; PERCUTANEOUS CORONARY INTERVENTION; PERSONALIZED MEDICINE; PHARMACIST; PHARMACOGENOMICS; PHARMACOKINETICS; PROFESSIONAL STANDARD; PHARMACOGENETICS; PHARMACY; PROCEDURES; TRENDS;

EVIDENCE-BASED MEDICINE; HUMANS; PATIENT CARE; PHARMACEUTICAL SERVICES; PHARMACISTS; PHARMACOGENETICS; PROFESSIONAL ROLE;

EID: 84908217499     PISSN: 02770008     EISSN: 18759114     Source Type: Journal    
DOI: 10.1002/phar.1481     Document Type: Article

References (49)

1. Motulsky AG, Qi M,. Pharmacogenetics, pharmacogenomics and ecogenetics. J Zhejiang Univ Sci B 2006; 7: 169-70.
2. Stamer UM, Musshoff F, Kobilay M, Madea B, Hoeft A, Stuber F,. Concentrations of tramadol and O-desmethyltramadol enantiomers in different CYP2D6 genotypes. Clin Pharmacol Ther 2007; 82: 41-7.
3. Poulsen L, Arendt-Nielsen L, Brosen K, Sindrup SH,. The hypoalgesic effect of tramadol in relation to CYP2D6. Clin Pharmacol Ther 1996; 60: 636-44.
4. Kiyotani K, Mushiroda T, Imamura CK, et al. Dose-adjustment study of tamoxifen based on CYP2D6 genotypes in Japanese breast cancer patients. Breast Cancer Res Treat 2012; 131: 137-45.
5. Mega JL, Close SL, Wiviott SD, et al. Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med 2009; 360: 354-62.
6. Lee S, Kim BH, Nam WS, et al. Effect of CYP2C19 polymorphism on the pharmacokinetics of voriconazole after single and multiple doses in healthy volunteers. J Clin Pharmacol 2012; 52: 195-203.
7. Evans WE, McLeod HL,. Pharmacogenomics-drug disposition, drug targets, and side effects. N Engl J Med 2003; 348: 538-49.
8. Table of Pharmacogenomic Biomarkers in Drug Labels. U.S. Food and Drug Administration; 2013 [updated May 22, 2014]. Available from http://www.fda.gov/drugs/scienceresearch/researchareas/pharmacogenetics/ucm083378.htm. Accessed June 4, 2014.
9. Gottesman O, Scott SA, Ellis SB, et al. The CLIPMERGE PGx Program: clinical implementation of personalized medicine through electronic health records and genomics-pharmacogenomics. Clin Pharmacol Ther 2013; 94: 214-7.
10. Johnson JA, Elsey AR, Clare-Salzler MJ, Nessl D, Conlon M, Nelson DR,. Institutional profile: University of Florida and Shands Hospital Personalized Medicine Program: clinical implementation of pharmacogenetics. Pharmacogenomics 2013; 14: 723-6.
11. O'Donnell PH, Bush A, Spitz J, et al. The 1200 patients project: creating a new medical model system for clinical implementation of pharmacogenomics. Clin Pharmacol Ther 2012; 92: 446-9.
12. Pulley JM, Denny JC, Peterson JF, et al. Operational implementation of prospective genotyping for personalized medicine: the design of the Vanderbilt PREDICT project. Clin Pharmacol Ther 2012; 92: 87-95.
13. Crews KR, Cross SJ, McCormick JN, et al. Development and implementation of a pharmacist-managed clinical pharmacogenetics service. Am J Health Syst Pharm 2011; 68: 143-50.
14. Weitzel KW, Elsey AR, Langaee TY, et al. Clinical pharmacogenetics implementation: approaches, success, and challenges. Am J Med Genet C Semin Med Genet 2014; 166: 56-67.
15. Hoffman JM, Haidar CE, Wilkinson MR, et al. PG4KDS: a model for the clinical implementation of pre-emptive pharmacogenetics. Am J Med Genet C Semin Med Genet 2014; 166: 45-55.
16. Shuldiner AR, Palmer K, Pakyz RE, et al. Implementation of pharmacogenetics: the University of Maryland personalized anti-platelet pharmacogenetics program. Am J Med Genet C Semin Med Genet 2014; 166: 76-84.
17. Bielinski SJ, Olson JE, Pathak J, et al. Preemptive genotyping for personalized medicine: design of the right drug, right dose, right time-using genomic data to individualize treatment protocol. Mayo Clin Proc 2014; 89: 25-33.
18. Nutescu EA, Drozda K, Bress AP, et al. Feasibility of implementing a comprehensive warfarin pharmacogenetics service. Pharmacotherapy 2013; 33: 1156-64.
19. Rudis MI, Brandl KM,. Position paper on critical care pharmacy services. Society of Critical Care Medicine and American College of Clinical Pharmacy Task Force on Critical Care Pharmacy Services. Crit Care Med 2000; 28: 3746-50.
20. Bishop MA, Streiff MB, Ensor CR, Tedford RJ, Russell SD, Ross PA,. Pharmacist-managed international normalized ratio patient self-testing is associated with increased time in therapeutic range in patients with left ventricular assist devices at an academic medical center. ASAIO J 2014; 60: 193-8.
21. Kogut SJ, Goldstein E, Charbonneau C, Jackson A, Patry G,. Improving medication management after a hospitalization with pharmacist home visits and electronic personal health records: an observational study. Drug Healthc Patient Saf 2014; 6: 1-6.
22. Ratanajamit C, Kaewpibal P, Setthawacharavanich S, Faroongsarng D,. Effect of pharmacist participation in the health care team on therapeutic drug monitoring utilization for antiepileptic drugs. J Med Assoc Thai 2009; 92: 1500-7.
23. Pedersen CA, Schneider PJ, Scheckelhoff DJ,. ASHP national survey of pharmacy practice in hospital settings: prescribing and transcribing-2013. Am J Health Syst Pharm 2014; 71: 924-42.
24. American Society of Health-Systems Pharmacists. DRAFT ASHP statement on the pharmacist's role in clinical pharmacogenomics. Bethesda, MD: American Society of Health-Systems Pharmacists. Available from http://www.ashp.org/DocLibrary/BestPractices/DraftDocs/DrftStPharmacogenomics.aspx. Accessed June 4, 2014.
25. Williams MS,. Genomic medicine implementation: learning by example. Am J Med Genet C Semin Med Genet 2014; 166: 8-14.
26. Mills R, Haga SB,. The clinical delivery of pharmacogenetic testing services: a proposed partnership between genetic counselors and pharmacists. Pharmaocogenomics 2013; 14: 957-68.
27. Scott SA, Sangkuhl K, Stein CM, et al. Clinical Pharmacogenetics Implementation Consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 update. Clin Pharmacol Ther 2013; 94: 317-23.
28. Johnson JA, Roden DM, Lesko LJ, Ashley E, Klein TE, Shuldiner AR,. Clopidogrel: a case for indication-specific pharmacogenetics. Clin Pharmacol Ther 2012; 91: 774-6.
29. Johnson JA, Burkley BM, Langaee TY, Clare-Salzler MJ, Klein TE, Altman RB,. Implementing personalized medicine: development of a cost-effective customized pharmacogenetics genotyping array. Clin Pharmacol Ther 2012; 92: 437-9.
30. Hicks JK, Crews KR, Hoffman JM, et al. A clinician-driven automated system for integration of pharmacogenetic interpretations into an electronic medical record. Clin Pharmacol Ther 2012; 92: 563-6.
31. Relling MV, Gardner EE, Sandborn WJ, et al. Clinical Pharmacogenetics Implementation Consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing. Clin Pharmacol Ther 2011; 89: 387-91.
32. Relling MV, Gardner EE, Sandborn WJ, et al. Clinical pharmacogenetics implementation consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing: 2013 update. Clin Pharmacol Ther 2013; 93: 324-5.
33. Crews KR, Gaedigk A, Dunnenberger HM, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for codeine therapy in the context of cytochrome P450 2D6 (CYP2D6) genotype. Clin Pharmacol Ther 2012; 91: 321-6.
34. Crews KR, Gaedigk A, Dunnenberger HM, et al. Clinical Pharmacogenetics Implementation Consortium Guidelines for Cytochrome P450 2D6 Genotype and Codeine Therapy: 2014 Update. Clin Pharmacol Ther 2014; 95: 376-82.
35. Muir AJ, Gong L, Johnson SG, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for IFNL3 (IL28B) genotype and PEG interferon-α-based regimens. Clin Pharmacol Ther 2014; 95: 141-6.
36. Genetics and Genomics Competency Center for Education, National Human Genome Research Institute. Pharmacist Pharmacogenomic Competencies and Outcomes. Bethesda, MD. Available from http://www.g-2-c-2.org/attachments/pdf/Pharmacist-Comp.pdf. Accessed June 4, 2014.
37. Accreditation Council for Pharmacy Education. Accreditation standards and guidelines for the professional program in pharmacy leading to the Doctor of Pharmacy degree. February 14, 2011. Available from https://www.acpe-accredit.org/deans/standards.asp. Accessed June 4, 2014.
38. McCullough KB, Formea CM, Berg KD, et al. Assessment of the pharmacogenomics educational needs of pharmacists. Am J Pharm Educ 2011; 75: 51.
39. Formea CM, Nicholson WT, McCullough KB, et al. Development and evaluation of a pharmacogenomics educational program for pharmacists. Am J Pharm Educ 2013; 77: Article 10.
40. Farrell CL, Pedigo NG, Messersmith AR,. Application of genomic principles to pharmacotherapy of cancer. Am J Pharm Educ 2014; 78: 55.
41. Drozda K, Labinov Y, Jiang R, et al. A pharmacogenetics service experience for pharmacy students, residents, and fellows. Am J Pharm Educ 2013; 77: 175.
42. Demmer LA, Waggoner DJ,. Professional medical education and genomics. Annu Rev Genomics Hum Genet 2014; 15: 3.1-3.10.
43. Feero WG, Green ED,. Genomics education for health care professionals in the 21st century. J Am Med Assoc 2011; 306: 989-90.
44. Salari K, Karczewski KJ, Hudgins L, Ormond KE,. Evidence that personal genome testing enhances student learning in a course on genomics and personalized medicine. PLoS ONE 2013; 8: e68853.
45. Owen JA, Assoc AP,. Integrating pharmacogenomics into pharmacy practice via medication therapy management. J Am Pharm Assoc 2011; 51: E64-74.
46. Phillips KA, Sakowski JA, Trosman J, Douglas MP, Liang SY, Neumann P,. The economic value of personalized medicine tests: what we know and what we need to know. Genet Med 2014; 16: 251-7.
47. Wong WB, Carlson JJ, Thariani R, Veenstra DL,. Cost effectiveness of pharmacogenomics: a critical and systematic review. Pharmacoeconomics 2010; 28: 1001-13.
48. Cohen J, Wilson A, Manzolillo K,. Clinical and economic challenges facing pharmacogenomics. Pharmacogenomics J 2013; 13: 378-88.
49. Cohen JP, Felix AE,. Personalized medicine's bottleneck: diagnostic test evidence and reimbursement. J Pers Med 2014; 4: 163-75.